The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service

By Nazir J.   Hart W.M.  

Journal of Medical Economics, Vol. 17, Iss. 6, 2014-06 ,pp. : 408-414

Informa Healthcare

Access to resources Recommend Favorite

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

By Herschorn S.   Pommerville P.   Stothers L.   Egerdie B.   Gajewski J.   Carlson K.   Radomski S.   Drutz H.   Schulz J.   Barkin J.   Hirshberg E.   Corcos J.  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 375-382

Informa Healthcare

Access to resources Recommend Favorite

Solifenacin for the treatment of overactive bladder

By Robinson Dudley   Cardozo Linda  

Therapy, Vol. 8, Iss. 6, 2011-11 ,pp. : 691-701

Future Medicine

Access to resources Recommend Favorite

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

By Speakman Mark   Khullar Vik   Mundy Anthony   Odeyemi Isaac   Bolodeoku John  

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2173-2179

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis

By Millard R. J.   Halaska M.  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 41-48

Informa Healthcare

Access to resources Recommend Favorite